



Infection report

Volume 9 Number 29 Published on: 21 August 2015

Bacteraemia

Voluntary surveillance of *Staphylococcus aureus* bacteraemia in England, Wales and Northern Ireland: 2007-2014

These analyses are based on data relating to diagnoses of *Staphylococcus aureus* (*S. aureus*) bloodstream infections during 2007 – 2014 in England, Wales and Northern Ireland (EWNI) extracted from Public Health England's (PHE) voluntary surveillance database Second Generation Surveillance System (SGSS).

SGSS comprises a communicable disease reporting module (CDR; formerly CoSurv/LabBase2) and an antimicrobial resistance module (AMR; formerly AmSurv). Most analyses presented here are based on data extracted from the CDR module of SGSS data on 17 July 2015.

The data presented here will differ in some instances from those in earlier publications partly due to the inclusion of late reports.

Rates of bacteraemia laboratory reports were calculated using mid-year resident population estimates for the respective year and geography [1,2]. Geographical analyses were based on the residential postcode of the patient if known (otherwise the GP postcode if known or, failing that, the postcode of the laboratory) with cases in England being assigned to the catchment area of one of 15 local PHE centres (PHECs) formed from administrative local authority boundaries.

The report includes analyses of the trends, patient demographic and geographical distribution, level of ascertainment, and antibiotic susceptibility among these bacteraemia episodes.

Key points:


- There were 9,100 *S. aureus* bacteraemia reports in 2014, comprising 8374 from England, 481 from Wales and 245 from Northern Ireland, representing a 1.7% increase in the number of *S. aureus* laboratory reports compared with 2013 (8944 reports). Similarly, the total number of all bacteraemia episodes also increased by 2.8% from 103,808 (2013) to 106,708 (2014).
- The incidence rates of total *S. aureus*, meticillin susceptible *S. aureus* (MSSA), and meticillin resistant (MRSA) was 15.4, 11.4 and 1.4 per 100,000 population in 2014, a decrease of 33.4%, 26.3% and 78.5%, respectively between 2007 and 2014.
- In 2014, the rate of MRSA bacteraemia per 100,000 population was highest in Northern Ireland (2.3), followed by England (1.4) and Wales (0.8), while the rate of MSSA bacteraemia per 100,000 population was highest in England (11.8), followed by Northern Ireland (10.7) and Wales (4.6).
- Within England, the highest incidence rate of MRSA bacteraemia was observed in Greater Manchester (2.9/100,000) and London (2.0/100,000), while Cheshire and Merseyside and Devon, Cornwall and Somerset reported the highest incidence of MSSA bacteraemias (17.6/100,000 and 15.5/100,000, respectively).
- In 2014, the MRSA bacteraemia rates per 100,000 population were highest amongst the elderly (>75 years). Males had higher bacteraemia rates than females in all age groups except for 1-4 and 15-44 years old.
- MSSA bacteraemia rates were the highest in those over 75 and below 1 year, with rates being higher in males in all age groups.
- Between 2010 and 2014, non-susceptibility of MRSA isolates to ciprofloxacin decreased from 90.4% to 70.5%, erythromycin from 67.6% to 56.1% and mupirocin from 9.6% to 6.2%, while it increased to fusidic acid from 13.5% to 18.0%.
- Resistance of MSSA isolates to erythromycin increased from 11.5% (2010) to 13.8% (2014).
- Comparison of voluntary reporting with the mandatory surveillance dataset showed a case ascertainment rate of 89.5% for MRSA and 62.2% for MSSA in 2014. The latter could reflect increased percentage of missing meticillin susceptibility data.

Trends in episode numbers and rates

There were 9,100 *S. aureus* bacteraemia reports made to the voluntary laboratory surveillance in 2014. This represents an increase of 1.7% from the 8,944 reports in 2013. In 2014, there were 853 (9.4%) reports of meticillin resistant *S. aureus* (resistance to meticillin, oxacillin, cloxacillin and cefoxitin). This is a small decrease (2.7%) from the previous year (877 reports). Similarly, the number of MSSA reports decreased by 3.6% from 6973 to 6725 between 2013 and 2014. Caution should be executed when interpreting these figures as 16.5% (1,522) of *S. aureus* bacteraemia reports were missing meticillin susceptibility data in 2014. This is a significantly large increase in comparison to 2007, when only 4.2% (548) reports had these data missing. Non-reporting of meticillin susceptibility has been increasing since then. The highest year-on-year increase in non-reporting was observed in England, in particular Greater Manchester, Kent, Surrey and Sussex and North East, and Northern Ireland in 2014.

The rate of all *S. aureus*, MRSA and MSSA bacteraemia per 100,000 in England, Wales and Northern Ireland decreased by 33.4%, 78.5% and 26.3%, respectively between 2007 and 2014 (Figure 1). However, the overall *S. aureus* bacteraemia rate per 100,000 population increased by 3.2% and 0.9% between 2012 and 2013 and again between 2013 and 2014, respectively.

Figure 1. Total *S. aureus*, MRSA, MSSA, and untested *S. aureus* bacteraemia rates per 100,000 population (England, Wales, and Northern Ireland): 2007-2014*



*Data extracted on 17 July 2015

Geographical distribution

The overall rate of *S. aureus* bacteraemia in England, Wales and Northern Ireland was 15.4 per 100,000 population in 2014. This was 6.6% decrease since 2010 (16.4/100,000) and 0.9% increase since 2013 (15.2/100,000). The *S. aureus* bacteraemia rate in England increased by 4.2% (14.8/100,000 to 15.4/100,000) between 2013 and 2014, while the rate in Wales and Northern Ireland decreased by 23.6% (19.1/100,000 to 13.3/100,000) and 30.4% (20.4/100,000 to 15.6/100,000).

The overall rate of MRSA bacteraemia per 100,000 population in England, Wales and Northern Ireland has been steadily decreasing between 2010 and 2014 (2.2 to 1.4) (Table 1a). The infection rate has decreased in most regions except for Avon, Gloucestershire and Wiltshire (increased from 1.5/100,000 to 1.9/100,000) and South Midlands and Hertfordshire (increased from 1.1/100,000 to 1.2/100,000) between 2010 and 2014. Northern Ireland (2.3/100,000) and England (1.4/100,000) were the countries with the highest rate of infection in 2014. Regionally, the highest MRSA bacteraemia rates were in Greater Manchester (2.9/100,000), London (2.0/100,000) and Avon, Gloucestershire and Wiltshire (1.9/100,000) in 2014. Regions with the lowest incidence included North East (0.7/100,000), Yorkshire and Humber (0.8/100,000) and Devon, Cornwall and Somerset (0.9/100,000) (Figure 2a).

Table 1b and Figure 2b show region- specific 5 year (2010-2014) MSSA bacteraemia rate and MSSA bacteraemia rate in 2014, respectively. The overall infection rate in England, Wales and Northern Ireland was 11.4 per 100,000 population in 2014, with England having the highest country rate of 11.8/100,000, followed by Northern Ireland (10.7/100,000) and Wales (4.6/100,000). Regions with the highest rate included Cheshire and Merseyside (17.6/100,000), Devon, Cornwall and Somerset (15.5/100,000) and Cumbria and Lancashire (14.0/100,000) in 2014. Regions with the lowest incidence included Thames Valley (8.4/100,000), London (9.6/100,000) and Yorkshire and Humber (9.8/100,000).

Table 1a. MRSA bacteraemia rate per 100,000 population by PHE Centre (England, Wales, and Northern Ireland): 2010-2014*

| Region | | Rate, per 100,000 population | | | | |
|--|-------------------------------------|------------------------------|------------|------------|------------|------------|
| | | 2010 | 2011 | 2012 | 2013 | 2014 |
| London | London | 2.8 | 1.9 | 2.9 | 2.0 | 2.0 |
| Midlands | South Midlands and Hertfordshire | 1.1 | 1.0 | 0.5 | 0.9 | 1.2 |
| | East Midlands | 2.1 | 1.6 | 0.9 | 1.3 | 1.2 |
| | Anglia and Essex | 2.1 | 1.5 | 1.4 | 1.2 | 1.8 |
| | West Midlands | 2.4 | 1.8 | 1.4 | 1.2 | 1.3 |
| | Cheshire and Merseyside | 2.3 | 2.3 | 1.5 | 1.9 | 1.7 |
| Northern | Cumbria and Lancashire | 1.9 | 1.1 | 0.9 | 1.2 | 1.1 |
| | Greater Manchester | 3.4 | 2.3 | 2.0 | 2.2 | 2.9 |
| | North East | 1.9 | 1.0 | 1.6 | 1.3 | 0.7 |
| | Yorkshire and Humber | 1.4 | 1.0 | 1.1 | 1.1 | 0.8 |
| | Avon, Gloucestershire and Wiltshire | 1.5 | 1.5 | 1.9 | 1.0 | 1.9 |
| Southern | Devon, Cornwall and Somerset | 1.9 | 1.6 | 1.3 | 0.9 | 0.9 |
| | Wessex | 1.6 | 1.2 | 1.1 | 0.7 | 1.0 |
| | Kent, Surrey and Sussex | 2.2 | 2.2 | 1.4 | 1.8 | 1.2 |
| | Thames Valley | 1.5 | 1.7 | 0.5 | 1.9 | 1.2 |
| | England | England | 2.1 | 1.6 | 1.5 | 1.4 |
| Northern Ireland | Northern Ireland | 6.2 | 5.0 | 4.0 | 4.0 | 2.3 |
| Wales | Wales | 2.2 | 1.7 | 1.8 | 1.1 | 0.8 |
| England, Wales and Northern Ireland | | 2.2 | 1.7 | 1.6 | 1.5 | 1.4 |


*Data extracted on 17 July 2015

Table 1b. MSSA bacteraemia rate per 100,000 population by PHE Centre (England, Wales and Northern Ireland): 2010-2014*

| Region | | Rate, per 100,000 population | | | | |
|--|-------------------------------------|------------------------------|-------------|-------------|-------------|-------------|
| | | 2010 | 2011 | 2012 | 2013 | 2014 |
| London | London | 11.1 | 9.8 | 9.9 | 10.5 | 9.6 |
| Midlands | South Midlands and Hertfordshire | 8.4 | 8.2 | 8.7 | 7.8 | 9.9 |
| | East Midlands | 14.6 | 15.4 | 13.4 | 12.6 | 13.3 |
| | Anglia and Essex | 12.8 | 13.0 | 11.5 | 11.9 | 11.6 |
| | West Midlands | 14.6 | 13.7 | 12.8 | 13.6 | 13.2 |
| | Cheshire and Merseyside | 17.3 | 17.5 | 15.8 | 17.9 | 17.6 |
| Northern | Cumbria and Lancashire | 13.4 | 11.7 | 12.8 | 15.0 | 14.0 |
| | Greater Manchester | 16.5 | 15.8 | 15.3 | 15.4 | 13.1 |
| | North East | 9.4 | 11.8 | 13.3 | 15.1 | 13.2 |
| | Yorkshire and Humber | 12.6 | 10.6 | 9.5 | 9.5 | 9.8 |
| | Avon, Gloucestershire and Wiltshire | 7.5 | 7.4 | 7.6 | 8.9 | 10.9 |
| Southern | Devon, Cornwall and Somerset | 17.9 | 15.7 | 13.5 | 15.7 | 15.5 |
| | Wessex | 11.2 | 10.8 | 11.4 | 11.0 | 10.1 |
| | Kent, Surrey and Sussex | 9.4 | 11.3 | 11.9 | 12.8 | 11.7 |
| | Thames Valley | 9.0 | 9.5 | 7.7 | 8.8 | 8.4 |
| | England | England | 12.3 | 12.0 | 11.5 | 12.1 |
| Northern Ireland | Northern Ireland | 15.4 | 15.3 | 16.4 | 15.0 | 10.7 |
| Wales | Wales | 5.2 | 6.0 | 5.6 | 5.7 | 4.6 |
| England, Wales and Northern Ireland | | 12.0 | 11.8 | 11.3 | 11.9 | 11.4 |


*Data extracted on 17 July 2015

Figure 2a. Geographical distribution of MRSA bacteraemia rates per 100,000 population (England, Wales and Northern Ireland): 2014*



*Data extracted on 17th July 2015

Figure 2b. Geographical distribution of MSSA bacteraemia rates per 100,000 population (England, Wales and Northern Ireland): 2014*



*Data extracted on 17 July 2015

Age and sex distribution


Figures 3a and 3b show age and sex distribution of MRSA and MSSA bacteraemia reports in 2014.

The highest rate of MRSA bacteraemia was observed in older age groups, namely in those over 75 years old (combined rate 7.2/100,000) and 65-74 years old (combined rate 3.2/100,000) and those below 1 (combined rate 2.1/100,000) (Figure 3a). On general, the infection incidence was higher in males than females with the exception of 1-4 (0.4/100,000 vs 0.5/100,000, respectively) and 15-44 (0.4/100,000 vs 0.5/100,000, respectively) age groups.

Similarly, the highest rate of MSSA bacteraemia was reported in those over 75 (combined rate 45.9/100,000), followed by those below 1 (combined rate 37.9/100,000) and 65-74 years old (combined rate 20.8/100,000) (Figure 3b). Males had higher infection rate across all age categories in comparison to females, with the bacteraemia rate being twice as high in males than females for age groups 45-64 (15.5/100,000 vs 7.0/100,000), 65-74 (28.2/100,000 vs 14.0/100,000) and over 75 (65.5/100,000 vs 31.9/100,000).

These overall patterns in MRSA and MSSA bacteraemia rates have been described in previous years and are comparable to those seen in the mandatory surveillance data [3, 4].


Figure 3a. MRSA age and sex rates† per 100,000 population (England, Wales and Northern Ireland): 2014*



† Rates were calculated using 2013 OSN mid-year population estimates

*Data extracted on 17 July 2015

Figure 3b. MSSA age and sex rates† per 100,000 population (England, Wales and Northern Ireland): 2014*



† Rates were calculated using 2013 OSN mid-year population estimates

*Data extracted on 17 July 2015

Antimicrobial susceptibility

The two most common Healthcare-Associated MRSA clones in the UK are the epidemic strains EMRSA-15 and EMRSA-16, which are usually resistant to ciprofloxacin and erythromycin [5]. Most voluntarily reported MRSA were resistant to these antibiotics, suggesting that EMRSA-15 and -16 continued to account for most of the MRSA bacteraemia reported under this scheme. Analysis of data from the British Society for Antimicrobial Chemotherapy Survey [6] shows that the proportion of EMRSA-16 decreased among all MRSA, while the proportion of EMRSA-15 increased between 2001 and 2007 [5]. A recent molecular epidemiological study of MRSA bacteraemia in England has shown that EMRSA-15, albeit still predominant, is declining and this has been associated with increase in clonal diversity. Furthermore, CC5 has replaced EMRSA-16 as the second most frequent lineage [7].

Tables 2a and 2b present trends in resistance to key antimicrobials for MRSA and MSSA between 2010 and 2014.

MRSA bacteraemia isolates had a high proportion (>70%) of susceptibility test results reported for majority of key antibiotics, except for linezolid (54%), erythromycin (57%), tigecycline (15%) and daptomycin (21%) in 2014. Similar patterns were observed for MSSA susceptibility test results, with lower reporting for vancomycin (62%), teicoplanin (55%), linezolid (60%), tigecycline (12%) and daptomycin (15%).

Ciprofloxacin resistance decrease in MRSA isolates by 19.9% between 2010 (90.4%) and 2014 (70.5%). Similar trend was observed in MSSA isolates during this 5 year period (7.5% in 2010 and 6.4% in 2014). Fluoroquinolone resistance is relatively stable in EMRSA-15 and -16, thus these changes in prevalence may be due to penetration by different clones [8].

Non-susceptibility to macrolides decreased in MRSA isolates by 8.0% between 2013 (64.0%) and 2014 (56.1%) and by 11.6% between 2010 (67.6%) and 2014 in comparison to MSSA isolates, where the macrolide resistance increased by 2.1% since 2013 (11.7%) and by 2.3% since 2010 (11.5%) (13.8% in 2014).

Mupirocin resistance in MRSA decreased between 2010 (9.6%) and 2014 (6.2%), while the resistance in MSSA isolates remained stable at around 1% during the same period.

Resistance to fusidic acid fluctuated between 13.5% and 20.4% in MRSA and between 12.7% and 13.7% in MSSA between 2010 and 2014.

Similarly, non-susceptibility to rifampicin in MRSA as well as MSSA showed no clear upward or downward trend between 2010 and 2014, being broadly around 2-7% and 2%, respectively.

Laboratories are asked to send any isolates suspected to have intermediate or full glycopeptides resistance, or resistance to newer agents used to treat staphylococcal infections (daptomycin, linezolid and tigecycline) to PHE's Antimicrobial Resistance and Healthcare Associated Infections (AMRHAI) Reference Unit, Colindale [9] for characterisation, including exploring the emergence and spread of new clones.

In 2014, resistance to vancomycin, tigecycline, linezolid and daptomycin remained low at 1% or less in MRSA and MSSA, though it is notable that AMRHAI observes small numbers of isolates where mutational resistance to linezolid or daptomycin has been selected during therapy, and occasional isolates with the *cfm* gene, a transferable linezolid resistance mechanism.

Table 2a. Antibiotic susceptibility for MRSA bacteraemia in England, Wales and Northern Ireland: 2010-2014*

| | 2010 | | 2011 | | 2012 | | 2013 | | 2014 | |
|----------------------|--------------|-------------|------------|-------------|------------|-------------|------------|-------------|------------|-------------|
| | No. Tested | % Resistant | No. Tested | % Resistant | No. Tested | % Resistant | No. Tested | % Resistant | No. Tested | % Resistant |
| Gentamicin | 1,088 | 9.1 | 847 | 10.2 | 782 | 10.7 | 758 | 9.5 | 726 | 10.7 |
| Ciprofloxacin | 1,005 | 90.4 | 784 | 87.5 | 751 | 87.0 | 695 | 81.9 | 692 | 70.5 |
| Linezolid | 645 | 0.2 | 526 | 0.8 | 550 | 0.4 | 509 | 0.0 | 461 | 0.2 |
| Erythromycin | 992 | 67.6 | 784 | 59.6 | 601 | 63.9 | 567 | 64.0 | 487 | 56.1 |
| Rifampicin | 1,069 | 4.0 | 809 | 6.6 | 740 | 2.0 | 688 | 5.2 | 687 | 3.1 |
| Mupirocin | 995 | 9.6 | 789 | 7.0 | 744 | 8.6 | 678 | 8.1 | 679 | 6.2 |
| Fusidic acid | 1,091 | 13.5 | 851 | 16.8 | 806 | 14.9 | 763 | 20.4 | 717 | 18.0 |
| Total Reports | 1,284 | | 999 | | 937 | | 877 | | 853 | |

* Data extracted on 17 July 2015

Table 2b. Antibiotic susceptibility for MSSA bacteraemia in England, Wales and Northern Ireland: 2010-2014*

| | 2010 | | 2011 | | 2012 | | 2013 | | 2014 | |
|----------------------|--------------|-------------|--------------|-------------|--------------|-------------|--------------|-------------|--------------|-------------|
| | No. Tested | % Resistant | No. Tested | % Resistant | No. Tested | % Resistant | No. Tested | % Resistant | No. Tested | % Resistant |
| Gentamicin | 5,753 | 1.0 | 5,887 | 0.9 | 5,778 | 1.3 | 6,067 | 1.3 | 5,782 | 1.4 |
| Ciprofloxacin | 4,813 | 7.5 | 4,872 | 7.6 | 4,952 | 7.2 | 5,164 | 6.9 | 4,975 | 6.4 |
| Linezolid | 2,918 | 0.1 | 3,358 | 0.1 | 3,714 | 0.1 | 4,205 | 0.0 | 4,058 | 0.1 |
| Erythromycin | 5,299 | 11.5 | 5,266 | 12.3 | 5,164 | 11.8 | 5,306 | 11.7 | 4,841 | 13.8 |
| Rifampicin | 5,179 | 1.7 | 5,259 | 1.5 | 5,270 | 1.9 | 5,586 | 2.1 | 5,375 | 1.7 |
| Mupirocin | 4,509 | 0.9 | 4,667 | 0.5 | 4,775 | 0.6 | 5,084 | 0.9 | 4,933 | 1.0 |
| Fusidic acid | 5,969 | 12.7 | 6,056 | 12.1 | 5,991 | 12.6 | 6,168 | 13.7 | 5,903 | 13.5 |
| Total Reports | 6,926 | | 6,824 | | 6,619 | | 6,973 | | 6,725 | |

*Data extracted on 17 July 2015

Ascertainment: Comparison of MRSA and MSSA positive specimens from the voluntary laboratory reporting scheme versus MRSA and MSSA infections from the mandatory surveillance scheme in England

The following data compare MRSA and MSSA bacteraemias reported to the voluntary laboratory surveillance scheme with those reported to the mandatory surveillance scheme. In order for the data to be comparable, the MSSA laboratory reports from the voluntary surveillance scheme have been limited to January 2011 onwards, when MSSA mandatory surveillance commenced. All voluntary bacteraemia reports were limited to those from England only (Wales and Northern Ireland do not take part in the English mandatory surveillance scheme).

The number of MRSA bacteraemia reports under voluntary and mandatory reporting schemes show similar decreasing trend (Table 3a), however, while the numbers of infection reports to the mandatory surveillance decreased by 52.1% between 2010 and 2014, it was only 34.0% under the voluntary scheme. There was a discord between MSSA bacteraemia reports between the two schemes between 2011 and 2014 (Table 3b); the number of reports increased year-on-year between 2012 and 2014 (8,737 in 2012, 9,143 in 2013, and 9,717 in 2014) under the mandatory scheme, while it decreased in 2014 (6,132 in 2013 and 6,044 in 2014) under the voluntary scheme.

The case ascertainment of MRSA bacteraemia reports to the voluntary scheme improved between 2010 and 2014 reaching its highest percentage in 2014 at 89.5%. Case ascertainment of MSSA reported to the voluntary scheme fluctuated between 2011 (68.1%) and 2014 (62.2%), with the highest ascertainment obtained in 2011.

Table 3a. Ascertainment of MRSA data for the mandatory and voluntary reporting schemes in England: 2010- 2014*

| Year | Voluntary reports | Mandatory reports | % Ascertainment |
|-------------|--------------------------|--------------------------|------------------------|
| 2010 | 1,060 | 1,631 | 65.0 |
| 2011 | 816 | 1,187 | 68.7 |
| 2012 | 753 | 934 | 80.6 |
| 2013 | 736 | 908 | 81.1 |
| 2014 | 700 | 782 | 89.5 |

* Data extracted on 17 & 20 July 2015

Table 3b. Ascertainment of MSSA data for the mandatory and voluntary reporting schemes in England: 2011- 2014*

| Year | Voluntary reports | Mandatory reports | % Ascertainment |
|------|-------------------|-------------------|-----------------|
| 2011 | 5,985 | 8,783 | 68.1 |
| 2012 | 5,762 | 8,737 | 65.9 |
| 2013 | 6,132 | 9,143 | 67.1 |
| 2014 | 6,044 | 9,717 | 62.2 |

* Data extracted on 17 & 20 July 2015

References

1. Office for National Statistics (ONS) mid-year population estimates for England and Wales, <http://www.ons.gov.uk/ons/rel/pop-estimate/population-estimates-for-uk--england-and-wales--scotland-and-northern-ireland/2013/index.html>
2. Northern Ireland Statistics and Research Agency (NISRA) mid-year population estimates for Northern Ireland. Available: <http://www.nisra.gov.uk/demography/default.asp17.htm>
3. PHE (2014). Voluntary reporting of *Staphylococcus aureus* bacteraemia in England, Wales and Northern Ireland, 2013. *HPR* 8(32), https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/346324/Voluntary_reporting_S_aureus_bacteraemia_England_Wales_Northern_Ireland_2013.pdf
4. PHE (2015). Annual Epidemiological Commentary: Mandatory MRSA, MSSA and *E. coli* bacteraemia and *C. difficile* infection data, 2014/15, https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/442952/Annual_Epidemiological_Commentary_FY_2014_2015.pdf
5. Ellington MJ, Hope R, Livermore DM, Kearns AM, Henderson K, Cookson BD, *et al* (2010). Decline of EMRSA-16 amongst methicillin-resistant *Staphylococcus aureus* causing bacteraemias in the UK between 2001 and 2007. *J Antimicrob Chemother* 65: 446–448. BSAC resistance surveillance website (bacteraemia data), <http://www.bsacsurv.org/reports/bacteraemia/>
7. Kearns A, Bou-Antou S, Pichon B, Yacoub M, Gow I, Ganner M, *et al* (2015). The changing epidemiology of MRSA bacteraemia in England-PVL on the increase? Poster session presented at: 25th European Congress of Clinical Microbiology and Infectious Diseases, Apr 25-28, Copenhagen, Denmark.
8. Knight GM, Budd EL, Whitney L, Thornley A, Al-Ghusein H, Planche T, *et al* (2012). Shift in dominant hospital-associated methicillin-resistant *Staphylococcus aureus* (HA-MRSA) clones over time. *J Antimicrob Chemother* 67(10): 2514-22.
9. Antimicrobial Resistance and Healthcare Associated Infections Reference Unit (AMRHAI), <https://www.gov.uk/amrhai-reference-unit-reference-and-diagnostic-services>.

Acknowledgement

These reports would not be possible without the weekly contributions from microbiology colleagues in laboratories across England, Wales, and Northern Ireland, as well as colleagues in the regional offices of Public Health England.